



(51) International Patent Classification:

A61K 31/53 (2006.01) C07D 403/12 (2006.01)

A61P 1/16 (2006.01)

(21) International Application Number:

PCT/CN2022/131297

(22) International Filing Date:

11 November 2022 (11.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/130083

11 November 2021 (11.11.2021) CN

PCT/CN2022/097426

07 June 2022 (07.06.2022) CN

(71) Applicant: TERNS PHARMACEUTICALS, INC.

[US/US]; 1065 East Hillsdale Blvd., Suite 100, Foster City, California 94404 (US).

(71) Applicant (for MG only): TERNS CHINA BIOTECH-

NOLOGY CO., LTD. [CN/CN]; #31, 42nd Floor, 1717 West Nanjing Road, Jinan District, Shanghai 200040 (CN).

(72) Inventors: JONES, Christopher T.; 1065 E. Hillsdale

Blvd., Suite 100, Foster City, California 94404 (US).

KLUCHER, Kevin; 1065 E. Hillsdale Blvd., Suite 100,

Foster City, California 94404 (US). CRITTENDEN, D.

Barry; 1065 E. Hillsdale Blvd., Suite 100, Foster City,

California 94404 (US). QUIRK, Erin K.; 1065 E. Hills-

dale Blvd., Suite 100, Foster City, California 94404 (US).

JIN, Feng; 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). DUAN, Matt; 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). GUO, Sheng; 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). BIAN, Jianwei; 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). DONG, Qianqian; 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US).

(74) Agent: LEE AND LI - LEAVEN IPR AGENCY LTD.; Unit 2202, Tower A, Beijing Pudi Hotel, No. 7, Jian Guo Men South Avenue, Dong Cheng District, Beijing 100005 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,


(54) Title: TREATMENT OF LIVER DISORDERS WITH A THR- β AGONIST

Figure 1

(57) Abstract: Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize treatment with a THR- β agonist.

DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*